Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tamara Thorn

Nurse Practitioner, Psychiatric/Mental Health Moraine, OH Nurse Practitioner

NPI 1053606152 CMS profile 11096593

5348 Lamme Rd, Moraine, OH 45439

Open in the dashboard

General payments

$88,859

552 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tamara Thorn of Moraine, OH is reported in the CMS Open Payments database as having received $88,859 across 552 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,479 171
2024 General $15,814 124
2023 General $15,144 92
2022 General $14,913 78
2021 General $5,509 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamara Thorn
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Tamara Thorn were reported at $37,479. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Tamara Thorn Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $5,509 $166 $54–$482 $132
2022 $14,913 $195 $66–$559 $149
2023 $15,144 $233 $82–$673 $160
2024 $15,814 $236 $84–$688 $164
2025 $37,479 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $27,179 152 payments
  2. Teva Pharmaceuticals USA, Inc. $23,402 106 payments
  3. Supernus Pharmaceuticals, Inc. $22,750 60 payments
  4. AbbVie, Inc. $12,809 121 payments
  5. Vanda Pharmaceuticals Inc. $632 13 payments
  6. Axsome Therapeutics, Inc. $341 8 payments
  7. Alkermes, Inc. $311 10 payments
  8. Tempus AI, Inc $260 8 payments
  9. ITI, Inc. $244 14 payments
  10. Lundbeck LLC $241 22 payments
  11. Other $689 38 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,993 56 payments
  2. Honoraria $18,100 11 payments
  3. Food and Beverage $9,939 434 payments
  4. Travel and Lodging $6,310 45 payments
  5. Consulting Fee $330 1 payment
  6. Education $187 5 payments
Products named General payments · program years 2021–2025
  1. REXULTI $26,931 135 payments
  2. Qelbree Viloxazine Hydrochloride $22,478 47 payments
  3. VRAYLAR $12,809 121 payments
  4. Austedo XR $11,780 45 payments
  5. AUSTEDO $10,694 27 payments
  6. UZEDY $818 33 payments
  7. ABILIFY MAINTENA $791 58 payments
  8. FANAPT $632 13 payments
  9. Auvelity $341 8 payments
  10. QELBREE Psychology $264 12 payments
  11. Other $2,550 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

887

Median for Nurse Practitioner: 389

Drug cost

$139,172

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 62 $87,702
Vraylar Cariprazine Hcl Brand 12 $17,111
Lurasidone Hcl Generic 31 $14,764
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 41 $5,104
Aripiprazole Generic 14 $2,892
Paliperidone Er Paliperidone Brand 11 $2,207
Alprazolam Generic 112 $1,583
Vilazodone Hcl Generic 14 $1,492
Prazosin Hcl Generic 11 $853
Divalproex Sodium Generic 25 $816

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$6,699

Medicare's payments for the services billed

Medicare patients

23

Average age 64

Services billed

86

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 70%
Arthritis 70%
High blood pressure 61%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $11,314
  • Lundbeck LLC $13
$11,327 62 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $2,977
$2,977 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $375
$375 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $221
$221 — —
VRAYLAR
  • AbbVie, Inc. $200
$200 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

552 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record